A federal jury has found a former research analyst liable for deceiving investors and the media by giving financial advice on companies he secretly held stock in.
Chadbourne & Parke LLP is continuing to expand its securities and white-collar group, part of a strategy to handle emerging opportunities after the passage of the Sarbanes-Oxley Act.
Johnson & Johnson’s pending $21.5 billion acquisition of Guidant, one of the largest mergers in the history of the medical device industry, puts the spotlight on the intense legal battle over the lucrative patents to drug-coated stents, attorneys say.
Yesterday's lawsuit against Refco's former excecutives by the commodities and foreign exchange broker's largest shareholder has law firms, banks, underwriters and accountants nervously wondering who's next.
Mired in an $11 billion accounting scandal, mortgage-buying giant Fannie Mae has released an updated laundry list of irregularities uncovered while researching its own books.
Bank of America and several other major banks that underwrote Refco’s initial public offering have been subpoenaed in connection with the investigation into the futures broker’s collapse.
Objecting to the terms of Refco Inc.’s bankruptcy, the Commodity Futures Trading Commission told a New York federal court it would oppose any move that erases liability of the company’s flagship futures branch Refco LLC, which will hit the auction-block as part of the deal.
Empowered by Capitol Hill and flush with cash, the Securities and Exchange Commission is continuing to widen its campaign against corporate fraud, with the latest numbers for 2005 showing the agency will again beat its record from the previous year. The trend is offset by a dramatic decrease in filings of private securities fraud lawsuits, which typically complement SEC investigations.
Embattled medical device maker Guidant Corporation can now add a federal investigation to its growing list of financial and legal worries, as the Securities and Exchange Commission has initiated a formal probe into the company’s product disclosures.
Stockholders used non-public information to illegally purchase call options in a Canadian gold company, just days before a $9.2 billion acquisition bid to create the world's largest gold mining company boosted its stock, according to a federal complaint by the U.S. Securities and Exchange Commission.
A renegade Estonian financial-services firm stole press releases from more than 200 U.S. public companies and traded on the news before it reached the public, the Securities and Exchange Commission claimed in an emergency federal court action filed Monday.
Merchant & Gould and Welsh & Katz said Tuesday they would merge to create one of the largest intellectual property specialty firms in the United States.
Barrier Therapeutics Inc. misled investors about the success of its clinical-stage biopharmaceuticals, according to a complaint filed by investors in federal court Friday.
Just two months after an impressive $585 million initial public offering, Refco Inc. has filed for bankruptcy, agreeing to sell its core futures brokerage for $785 million in order to salvage some of its other subsidiaries.
As futures broker Refco’s financial situation becomes increasingly dire, litigation against the company continues to mount, now encompassing the banks that underwrote Refco’s initial public offering.
With the acquisition of California mid-sized firm Hancock Rothert & Bunshoft LLP, Duane Morris LLP is bolstering its California presence and taking another step toward becoming a coast-to-coast powerhouse.
Litigation costs will be slashed by a patent reform bill advancing on Capitol Hill, even though the bill has been watered down, says Herbert C. Wamsley, who heads up the influential Intellectual Property Owners Association.
With the wipe-out of inventor Jerome Lemelson’s controversial patent portfolio for the bar code scanner and industrial robotic vision, Ropes & Gray’s Fish & Neave unit can carve yet another notch in its belt.
U.S. companies expect to spend more money on patent litigation in coming years amid a continued decline in patent quality, a survey of executives shows.
Pfizer Inc.’s glaucoma drug Xalatan is off limits to generics manufacturer Par Pharmaceutical Inc., following a decision in Pfizer’s favor by the U.S. Court of Appeals for the Federal Circuit.